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introduction: It is unclear what factors determine the use of anticoagulants among patients presenting with acute coronary syndrome (ACS), in 
which the use of single (SAPT) or dual (DAPT) antiplatelet therapy is required.
methods: We retrospectively evaluated clinical factors associated with in-hospital and post-discharge anticoagulant use among 5378 ACS 
patients enrolled in the Intermountain Heart Collaborative Study from 2004-2009. Multivariable logistic regression analyses were used to determine 
predictors of anticoagulant use in patients receiving SAPT or DAPT.
results: In hospital, 99% of patients received an anticoagulant (83% heparin, 16% low molecular weight heparin, 12% warfarin, 8% other), 80% 
received DAPT, and 18% SAPT. Post-discharge, only 9% received anticoagulation (warfarin); 77% received DAPT and 20% SAPT (Table). Warfarin was 
prescribed in 7% of DAPT and 17% of SAPT patients; <1% received warfarin alone. Warfarin was used more frequently in patients with myocardial 
infarction (MI) (ST-elevation MI [STEMI] 11%, non-STEMI 10%, unstable angina 7%).
conclusion: Among >5000 ACS patients, in-hospital use of anticoagulants was nearly universal. Post-discharge, warfarin use was rare and usually 
associated with the traditional indications of venous thromboembolism or atrial fibrillation. It was more frequently used with SAPT and prescribed 
slightly more frequently to STEMI and non-STEMI patients. How anticoagulation decisions affect long-term outcome requires further study.
